BofA Upgrades Apellis as Empaveli Shows Strong Early Momentum
Bank of America upgraded Apellis to Buy, citing undervalued shares and strong early uptake of Empaveli in rare kidney diseases.
/ 4 items
#APLS↓
Wells Fargo Upgrades Apellis to Overweight - $32 Price Target
Wells Fargo raises Apellis to Overweight with $32 target, citing stable Syfovre sales and strong Empaveli launch potential. Stock could gain 15-20%.
Goldman Sachs Downgrades Apellis to Sell
Goldman Sachs cut Apellis stock to "Sell," lowering the price target to $18. Risks include slow near-term growth and lower Syfovre sales.
Apellis' EMPAVELI: First Treatment for Rare Kidney Diseases
FDA-approved EMPAVELI (pegcetacoplan) for C3G & IC-MPGN in patients 12+. Shows 68% proteinuria reduction, kidney function stabilization, and C3 deposit clearance. A transformational therapy for 5,000 US patients.